| scholarly article | Q13442814 |
| P2093 | author name string | Kate Jones | |
| Ian M Tomlinson | |||
| Lucy J Holt | |||
| Amrik Basran | |||
| Jennifer Chorlton | |||
| Laurent S Jespers | |||
| Neil D Brewis | |||
| P433 | issue | 5 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 283-288 | |
| P577 | publication date | 2008-04-02 | |
| P1433 | published in | Protein Engineering Design and Selection | Q15762396 |
| P1476 | title | Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs | |
| P478 | volume | 21 |
| Q92239553 | A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer |
| Q33743756 | Adnectins: engineered target-binding protein therapeutics |
| Q38292087 | Albumin and its application in drug delivery |
| Q23915273 | Amelioration of pathology by ELR-CXC chemokine antagonism in a swine model of airway endotoxin exposure |
| Q34445142 | Anti-TNFα domain antibody construct CEP-37247: Full antibody functionality at half the size |
| Q37679663 | Antibody fragments: hope and hype |
| Q37998496 | Candidate antibody-based therapeutics against HIV-1. |
| Q37597698 | Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. |
| Q92585782 | Considerations for the Design of Antibody-Based Therapeutics |
| Q55284988 | Correlation Between Protein Primary Structure and Soluble Expression Level of HSA dAb in Escherichia coli. |
| Q39540318 | Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding |
| Q90211949 | David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments |
| Q34752052 | Development and characterization of small bispecific albumin-binding domains with high affinity for ErbB3. |
| Q37981866 | Drug development: longer-lived proteins. |
| Q33919030 | Efficient generation of single domain antibodies with high affinities and enhanced thermal stabilities |
| Q35044156 | Engineered antibody variable and constant domains as therapeutic candidates |
| Q42770832 | Escherichia coli surface display for the selection of nanobodies |
| Q50437891 | Expression of anti-tumor necrosis factor alpha (TNFα) single-chain variable fragment (scFv) in Spirodela punctata plants transformed with Agrobacterium tumefaciens |
| Q34568391 | Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain |
| Q39675238 | Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life |
| Q37327316 | Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding |
| Q45861473 | Factor IX oligomerization underlies reduced activity upon disruption of physiological conditions. |
| Q50948280 | Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection. |
| Q92508905 | Fusion of Lysostaphin to an Albumin Binding Domain Prolongs Its Half-Life and Bactericidal Activity in the Systemic Circulation |
| Q48191615 | Fusion of Ssm6a with a protein scaffold retains selectivity on NaV 1.7 and improves its therapeutic potential against chronic pain. |
| Q35212305 | Fusion of a short peptide that binds immunoglobulin G to a recombinant protein substantially increases its plasma half-life in mice |
| Q27701821 | Fusion to a highly stable consensus albumin binding domain allows for tunable pharmacokinetics |
| Q85342192 | GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety |
| Q38989309 | Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation. |
| Q46271471 | Half-life extension using serum albumin-binding DARPin® domains. |
| Q57050328 | Human and mouse albumin bind their respective neonatal Fc receptors differently |
| Q38116457 | IL-1Ra and its delivery strategies: inserting the association in perspective. |
| Q35759488 | Identification of cross-reactive single-domain antibodies against serum albumin using next-generation DNA sequencing |
| Q38020872 | Immunoglobulin domains in Escherichia coli and other enterobacteria: from pathogenesis to applications in antibody technologies |
| Q34724092 | Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain |
| Q39167522 | In vitro-engineered non-antibody protein therapeutics |
| Q34168363 | Introduction to current and future protein therapeutics: a protein engineering perspective |
| Q38167818 | Latent cytokines for targeted therapy of inflammatory disorders. |
| Q34603307 | Liver-targeting of interferon-alpha with tissue-specific domain antibodies |
| Q50926502 | Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys. |
| Q38116065 | Monoclonal antibody treatments for rheumatoid arthritis |
| Q57260221 | Non-Antibody Scaffolds as Alternative Therapeutic Agents |
| Q36674580 | Novel Interaction Mechanism of a Domain Antibody-based Inhibitor of Human Vascular Endothelial Growth Factor with Greater Potency than Ranibizumab and Bevacizumab and Improved Capacity over Aflibercept |
| Q37367934 | Novel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the rat |
| Q39771050 | Peptide aptamer microarrays: bridging the bio-detector interface. |
| Q35768046 | Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension |
| Q35090876 | Pharmacokinetic characteristics, pharmacodynamic effect and in vivo antiviral efficacy of liver-targeted interferon alpha |
| Q37778732 | Research and development of next generation of antibody-based therapeutics |
| Q35005394 | Selection of single domain antibodies from immune libraries displayed on the surface of E. coli cells with two β-domains of opposite topologies |
| Q39137483 | Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures |
| Q34420356 | Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion |
| Q51071921 | Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis. |
| Q38236706 | Shark variable new antigen receptor biologics - a novel technology platform for therapeutic drug development |
| Q33449506 | Single domain antibodies against the collagen signalling receptor glycoprotein VI are inhibitors of collagen induced thrombus formation |
| Q90211941 | Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases |
| Q42557601 | Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics |
| Q38217595 | Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects |
| Q49358130 | Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human VH/VL Single-Domain Antibodies from In Vitro Display Libraries |
| Q84830552 | Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs its therapeutic potentials |
| Q37278012 | Therapeutic advances in rheumatology with the use of recombinant proteins |
| Q37491236 | Therapeutic antibodies: successes, limitations and hopes for the future |
| Q27027238 | Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics |
Search more.